Table 3.

Bivariate Analysis of the Respondent’s Clinical Characteristics in Relation to the Decrease in the Glycemic Parameter of Post-Prandial Blood Glucose (PPBG)

Clinical Characteristics		Changes in PPBG				p	RR	95% CI
		Decreasing		Not Decreasing
		n	(%)	n	(%)
Treatment	Treated	56	90.3	6	9.7	0.001	1.341	1.168–1.540
	Untreated	101	67.3	49	32.7
Oral drugs	Yes	61	83.6	12	16.4	0.034	1.210	1.041–1.407
	No	96	69.1	43	30.9
Insulin	Yes	3	100	0	0.0	0.570	1.357	1.252–1.472
	No	154	73.7	55	26.3
Comorbid hypertension	No	59	69.4	26	30.6	0.270	0.900	0.759–1.066
	Yes	98	77.2	29	22.8
Comorbid dyslipidemia	No	66	75.0	22	25.0	0.916	1.022	0.870–1.200
	Yes	91	73.4	33	26.6
Body mass index	Decreasing	21	67.7	10	32.3	0.518	0.902	0.697–1.166
	Not decreasing	136	75.1	45	24.9
Cholesterol levels	Decreasing	79	77.5	23	22.5	0.353	1.092	0.932–1.281
	Not decreasing	78	70.9	32	29.1
LDL levels	Decreasing	83	76.1	26	23.9	0.577	1.060	0.903–1.244
	Not decreasing	74	71.8	29	28.2
HDL levels	Not decreasing	78	76.5	24	23.5	0.538	0.939	0.801–1.101
	Decreasing	79	71.8	31	28.2
Systolic blood pressure	Decreasing	80	77.7	23	22.3	0.312	1.099	0.938–1.289
	Not decreasing	77	70.6	32	29.4
Diastolic blood pressure	Decreasing	86	73.5	31	26.5	0.963	0.984	0.838–1.154
	Not decreasing	71	74.7	24	25.3

Notes: Data are expressed in n (%). The total number (n) of treated group = 62. The total number (n) of the untreated group = 150. Bold values are statistically significant (p-value < 0.05).

Abbreviations: PPBG, post-prandial blood sugar; LDL, low-density lipoprotein; HDL, high-density lipoprotein; RR, relative risk; 95% CI, 95% confidence interval.